These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 27098006)

  • 1. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
    Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
    Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
    Kaplan HG; Malmgren JA; Atwood MK
    BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
    Kuendgen A; Lauseker M; List AF; Fenaux P; Giagounidis AA; Brandenburg NA; Backstrom J; Glasmacher A; Hasford J; Germing U;
    Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
    Rollison DE; Komrokji R; Lee JH; Hampras S; Fulp W; Fisher K; Baz R; Nishihori T; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Sullivan D; Alsina M; Dalton W; Shain KH
    Leuk Lymphoma; 2017 Mar; 58(3):560-568. PubMed ID: 27424609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
    Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
    J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
    Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Attar EC; Amrein PC; Fraser JW; Fathi AT; McAfee S; Wadleigh M; Deangelo DJ; Steensma DP; Stone RM; Foster J; Neuberg D; Ballen KK
    Leuk Res; 2013 Sep; 37(9):1016-20. PubMed ID: 23773898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
    Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
    Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
    Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
    Kaplan H; Malmgren J; De Roos AJ
    Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
    Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
    Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma.
    Reiss J; Link B; Ruan J; Furman R; Coleman M; Leonard J; Martin P
    Leuk Lymphoma; 2015; 56(10):2870-5. PubMed ID: 25676037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
    Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
    Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
    Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
    Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.